Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Surgical Science Sweden ABSUSRF -2.20%82 Return-on-Tangible-Asset is 5.65% as of Mar. 2026, which is 49% below its 10-year median of 11.13. GuruFocus rates SUSRF with a GF Scoreâ„¢ of 82/100 and a GF Valueâ„¢ of $14.25 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 57.71% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Surgical Science Sweden AB's annualizedNet Income for the quarter that ended in Mar. 2026 was $8.0 Mil. Surgical Science Sweden AB's average total tangible assets for the quarter that ended in Mar. 2026 was $141.6 Mil. Therefore, Surgical Science Sweden AB's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2026 was 5.65%.
The historical rank and industry rank for Surgical Science Sweden AB's Return-on-Tangible-Asset or its related term are showing as below:
SUSRF'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -6.56 Med: 11.13 Max: 23.66
Current: 4.1
During the past 11 years, Surgical Science Sweden AB's highest Return-on-Tangible-Asset was 23.66%. The lowest was -6.56%. And the median was 11.13%.
SUSRF's Return-on-Tangible-Asset is ranked better than 57.71% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 2.5
vs SUSRF: 4.10
Surgical Science Sweden AB (OTCPK:SUSRF) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companyÂ’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companyÂ’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Surgical Science Sweden AB Return-on-Tangible-Asset Related Terms
Surgical Science Sweden AB Return-on-Tangible-Asset Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Surgical Science Sweden AB Return-on-Tangible-Asset Chart
SUSRF vs VEEV, BTSG, TEM: Return-on-Tangible-Asset Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Return-on-Tangible-Asset vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
What does a Return-on-Tangible-Asset of 5.65% mean?
Surgical Science Sweden AB (SUSRF) has a Return-on-Tangible-Asset of 5.65% as of Mar. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Surgical Science Sweden AB and its competitors. This is 49% below median its historical median of 11.13. According to the industry distribution chart, Surgical Science Sweden AB ranks #288 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 42.3%.
Is Surgical Science Sweden AB's Return-on-Tangible-Asset too high?
Surgical Science Sweden AB's current Return-on-Tangible-Asset of 5.65% is 49% below median its 10-year median of 11.13. The Healthcare Providers & Services industry median Return-on-Tangible-Asset is 2.50. Surgical Science Sweden AB's value of 5.65% is 126% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #288 out of 681 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Scoreâ„¢ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Return-on-Tangible-Asset compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #288 out of 681 companies for Return-on-Tangible-Asset. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Return-on-Tangible-Asset is 2.50. Surgical Science Sweden AB's value of 5.65% is 126% above this benchmark. While the company's 10-year median is 11.13 vs. the industry median of 2.50, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Healthcare Providers & Services company?
The median Return-on-Tangible-Asset among Healthcare Providers & Services companies is 2.50, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Return-on-Tangible-Asset of 5.65% is 126% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Return-on-Tangible-Asset is 2.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Return-on-Tangible-Asset is 5.65%, which is 49% below median its own 10-year median of 11.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.25, compared to a current price of $4.00 — trading 71.9% below its estimated fair value. The current Return-on-Tangible-Asset is 5.65%, which is 49% below median its 10-year median of 11.13 and 126% above the Healthcare Providers & Services industry median of 2.50. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Return-on-Tangible-Asset is 5.65% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 71.9% below its estimated GF Value™ of $14.25.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Return-on-Tangible-Asset: 5.65% (49% below median its 10-year median of 11.13)
GF Value™: $14.25 vs. price of $4.00 (71.9% below fair value)
Industry Position: 126% above the Healthcare Providers & Services median (#288 of 681)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
